ZT-12-037-01
Based on 1 publication(s) in Google Scholar
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.06%
- CAS No.: 2328073-61-4
- Formule: C21H31N5O2
- Masse moléculaire:385.50
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ZT-12-037-01
More
Activité biologique
ZT-12-037-01 (3 μM; 14 days) significantly inhibits mutant NRAS-STK19-driven melanocyte colony formation and proliferation[1].? ZT-12-037-01 (0-3 μM) has an inhibitory effects of ZT-12-037-01 on STK19WT and STK19D89N-activated NRAS phosphorylation in HPMs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CDK4 (R24C) melanocyte cells; hTERT melanocyte cells; p53DD melanocyte cells
-
Concentration:3 μM
-
Incubation Time:14 days
-
Result:Inhibited melanocyte proliferation.
-
Cell Line:STK19WT and STK19D89N
-
Concentration:0 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM
-
Incubation Time:
-
Result:Inhibited NRAS phosphorylation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SK-MEL-2 xenograft melanoma nude mice with hTERT/p53DD/CDK4(R24C) melanocytes[1]
-
Dosage:25 mg/kg; 50 mg/kg
-
Administration:Intraperitoneally injection; 21 days; once a day
-
Result:Inhibited growth of SK-MEL-2 xenograft melanoma.
Chemical Information
-
CAS No. 2328073-61-4
-
Appearance Solid
-
Masse moléculaire 385.50
-
Formule C21H31N5O2
-
Color White to off-white
-
SMILES
COC1=CC2=NC(NC3CC3)=NC(NC4CCN(C(C)C)CC4)=C2C=C1OC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Transl Med
CRISPR/Cas9 library screening reveals that STK19 has synergistic antitumor effects when combined with cisplatin on tongue squamous cell carcinoma. [Abstract]2025 Oct 21;23(1):1142. PMID: 41121307
Solvant et solubilité
1M HCl : 100 mg/mL (259.40 mM; Need ultrasonic)
DMSO : 50 mg/mL (129.70 mM; ultrasonic and adjust pH to 2 with 1M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (12.97 mM); Suspended solution; Need ultrasonic
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 1M HCl | 1 mM | 2.5940 mL | 12.9702 mL | 25.9403 mL | 64.8508 mL |
| 5 mM | 0.5188 mL | 2.5940 mL | 5.1881 mL | 12.9702 mL | |
| 10 mM | 0.2594 mL | 1.2970 mL | 2.5940 mL | 6.4851 mL | |
| 15 mM | 0.1729 mL | 0.8647 mL | 1.7294 mL | 4.3234 mL | |
| 20 mM | 0.1297 mL | 0.6485 mL | 1.2970 mL | 3.2425 mL | |
| 25 mM | 0.1038 mL | 0.5188 mL | 1.0376 mL | 2.5940 mL | |
| 30 mM | 0.0865 mL | 0.4323 mL | 0.8647 mL | 2.1617 mL | |
| 40 mM | 0.0649 mL | 0.3243 mL | 0.6485 mL | 1.6213 mL | |
| 50 mM | 0.0519 mL | 0.2594 mL | 0.5188 mL | 1.2970 mL | |
| 60 mM | 0.0432 mL | 0.2162 mL | 0.4323 mL | 1.0808 mL | |
| 80 mM | 0.0324 mL | 0.1621 mL | 0.3243 mL | 0.8106 mL | |
| 100 mM | 0.0259 mL | 0.1297 mL | 0.2594 mL | 0.6485 mL |
ZT-12-037-01 Related Classifications
HY-122866 Related Classifications
Powered by Bioz